This study examined the response of the Eker rat to nephrotoxi c compounds and to genotoxic nonrenal carcinogens. Groups of male Eker rats received either no treatment; a vehicle treatment; treatment with a noncarcinogeni c nephrotoxin (aluminum nitrilotriacetate, 2 mg/kg/day of aluminum, intraperitoneally, 3 days per week or cyclosporine A, 30 mg/kg/day, orally by gavage, 7 days/week); or treatment with a genotoxic nonrenal carcinogen (furan, 8 mg/kg/day, orally by gavage, 5 days/week or 2,4-diaminotoluene , 6.5 mg/kg/day, orally by gavage, 7 days/week or 2-nitropropane , 89 mg/kg/day, orally by gavage, 3 days/week). Duration of treatment was 4 and/or 6 months. Tissues from the Eker rats were evaluated microscopically and number s of proliferative renal lesions were counted. Administration of nephrotoxic compound s (Al-NTA and cyclosporine) signi cantly increased the number of preneoplasti c and neoplastic renal lesions in the Eker rat compared to concurrent vehicle controls. The genotoxic nonrenal carcinogens had no consistent effect on numbers of preneoplastic or neoplastic renal lesions and did not produce neoplasms in the expected target organ (liver).
INTRODUCTION
The genome of the Eker rat contains an insertion of a rat endogenous retroviral element into the Tsc2 gene, which is the rat homologue of the human tuberous sclerosis 2 (TSC2) gene (20, 22) . Mutations to either TSC2 (on chromosome 16p13.3) (2) or TSC1 (on chromosome 9q34) (17) are the cause of tuberous sclerosis (TSC), an autosomal dominant disorder in humans. Tuberous sclerosis is characterized by neurologic disorders (seizures, mental retardation, autism) and a variety of hamartomas or other proliferative lesions in the brain, heart, skin, and kidneys (1, 5) . The gene product of TSC2, a membrane-associated GTPase activating protein called tuberin, colocalizes to cytoplasmic vesicles with hamartin, the product of the TSC1 gene, and may act as a hamartin chaperone (15) . Tuberin may play a role in cell cycle control (2) . The Eker rat has some of the phenotypic characteristics of tuberous sclerosis (23) and is a model of dominantly inherited cancer susceptibility to renal cell carcinoma and mesenchymal tumors in other organs (4, 7) . A high proportion of the Eker rat renal cell carcinomas, uterine leiomyomas, and pituitary adenomas, as well as many of the hamartomas observed in human TSC patients, have deletions of the wild-type (functional) TSC2 allele (5, 11, 12, 21) . This suggests that the TSC2 gene has a tumor suppressor function.
The ICH Guidance on Testing for Carcinogenicity of Pharmaceuticals states that an assay in a short or medium-term in vivo rodent test system may be conducted as an alternative to a long-term carcinogenicity study in a second rodent species (10) . It has been suggested that the best models to complement the 2-year rodent bioassay are those that have the capacity to respond broadly to potential carcinogens, but many of the evaluated models (eg, the Tg.AC mouse) have endpoints that are either stereotypic or early "reporter" responses (17) . Previously published reports of the response of the Eker rat to carcinogen exposure suggested that this model might be useful for the early detection of carcinogens. Treatment with radiation or dimethylnitrosamine (DMN) and transplacental exposure to N-ethyl-N-nitrosourea (ENU) all produce increased numbers of renal cell carcinomas in Eker rats, consistent with Knudsen's 2-hit hypothesis of carcinogenesis (6, 9, 18) .
To evaluate the potential utility of the Eker rat as an adjunct to the 2-year rat bioassay, we examined the response of this model to a battery of chemicals for which adequate published data was available with respect to their genotoxicity, carcinogenicity, and nephrotoxicity in 2-year rat bioassays. One objective of these studies was to determine if the Eker rat would respond in a relatively short period of time (4-6 months of treatment) to known carcinogens, either with results similar to those of the 2-year rodent bioassay or with a "reporter" response (increased incidence, i.e., numbers of animals with tumors, or increased total numbers of renal neoplasms). A second and corollary objective was to determine if the Eker rat would have a renal neoplastic response to nephrotoxins that were classi ed as noncarcinogenic based on 2-year rodent bioassay results. Each chemical was selected, based on results of genotoxicity assays and 2-year rodent bioassays, to be either a genotoxic carcinogen that produced neither renal toxicity nor renal neoplasms or to be a nephrotoxin that was not genotoxic and not a carcinogen in the kidney or any other target organ. The battery included 3 genotoxic nonrenal carcinogens (2,4-diaminotoluene and 2-nitropropane, both hepatic carcinogens, and furan, a biliary carcinogen); and 2 noncarcinogenic nephrotoxins (aluminum nitrilotriacetic acid and cyclosporine A). The duration of treatment was limited to 4-6 months to minimize the contribution of age to the multiplicity and incidence of neoplasia, because the background rate of spontaneous renal neoplasia in Eker rats approaches 100% at 1 year of age (3) .
MATERIALS AND METHODS

Animals
The use of the animals in these studies followed the guidelines provided in the Guide for the Care and Use of Laboratory Animals (1996) and the protocols were approved by the Institutional Animal Care and Use Committees of Integrated Laboratory Systems, Inc. and Red eld Laboratories, Inc. Male Eker rats (Long Evans background strain) were obtained from the University of Texas, MD Anderson Cancer Center, Smithville, Texas. The rats had been genotyped by multiplex polymerase chain reaction (PCR) using DNA isolated from ear tissue samples and 3 primers for the Tsc2 gene (Tsc2-3820, Tsc2-3846 and Tsc2-MTA2).
Phase I:
The rats were about 10 weeks old at the initiation of the study and weighed 160-300 g. Rats were housed in pairs, in polycarbonate cages with hardwood bedding, under environmental conditions of controlled temperature and humidity. A 12-hour light/12-hour dark photo cycle was maintained. Basal diet (NIH-07 open formula, Ziegler Brothers, Gardener, PA) and tap water were provided ad libitum to all animals.
Phase II:
The rats were about 7-9 weeks old and weighed 136-300 g at the initiation of the study. Rats were housed individually in stainless steel cages under environmental conditions of controlled temperature and humidity. A 12-hour light/12-hour dark photo cycle was maintained. Basal diet (NIH-07 open formula, Ziegler Brothers, Gardener, PA) and tap water were provided ad libitum to all the animals.
Chemicals
Phase I: The 2,4-diaminotoluene (2,4-DAT, CAS No. 95-80-7, Sigma-Aldrich, Inc, Milwaukee, WI) was prepared in a vehicle of 0.01 M HCl at a concentration of 3.25 mg/mL. The 2-nitropropane (2-NP, CAS No. 79-46-9, Sigma-Aldrich, Inc) was prepared in a vehicle of 10% Emulphor (EL-620, 
Experimental Design
The experimental design of Phase I is summarized in Table 1 . The experimental design of Phase II is summarized in Table 2 . Animals were randomized into groups by weightorder distribution in both Phase I and Phase II. Animals in Phase I were euthanized and necropsied after 4 months on study. Animals in Phase II were euthanized and necropsied after either 4 or 6 months on study. Complete necropsies were performed on all animals and a full set of tissues was collected. Tissues were xed in 10% neutral buffered formalin, except for testes and epididymides ( xed in Bouin's solution) and eyes ( xed in Davidson's solution). All collected tissues were trimmed and processed, embedded in paraf n, stained with hematoxylin-eosin, and examined by light microscopy. Numbers of hyperplastic tubules, adenomas, and carcinomas, identi ed based on previously described criteria (3), were counted in 1 longitudinal and 1 cross section of kidney. Grossly identi able renal masses that would not have been included in the standard sections of kidney were also examined histologically and, if neoplastic, were included in the count of neoplastic lesions.
Statistical Analysis
All statistical analyses were performed using the SAS system, version 6.12.
Phase I: The hypotheses tested were that the mean numbers of renal hyperplastic tubules, adenomas, carcinomas, all renal neoplasms, and all neoplasms, were higher in treated animals than the corresponding vehicle control animals. Two testing methods were used: a Likelihood Ratio Test (LRT) and a Nonparametric Mann-Whitney test. All statistical results were reported as an upper-tailed test (control < treated) with a 5% signi cance level.
Phase II: Quantitative and qualitative data were analyzed. Quantitative data were numbers of renal hyperplastic tubules, numbers of renal adenomas, and total numbers of tumors. Total numbers of tumors was calculated for each animal by summing the numbers of renal adenomas and carcinomas and other malignant and benign neoplasms observed in that animal. The effect of treatment and duration for quantitative data was analyzed using a two-way factorial analysis of variance (ANOVA) model. Qualitative data included renal adenoma incidence, renal carcinoma incidence, and total tumor incidence, where incidence was the number of animals bearing each given lesion. The effect of treatment and duration for qualitative data were analyzed with a logistic model using weighted least squares estimation. Statistical conclusions were made using a 2-tailed 5% signi cance level.
RESULTS
Total numbers of preneoplastic and neoplastic lesions and their incidence (i.e., number of lesion-bearing animals), for each lesion type, are outlined in Table 3 (2,4-DAT), Table 4 (2-NP), Tables 5 and 6 (furan), Tables 7 and 8 (Al-NTA), and Tables 9 and 10 (cyclosporine). Incidence is presented in the tables as percent incidence (percentage of animals in the group with each lesion type) to facilitate comparisons between groups of unequal size. Numbers of lesions are presented as the total number for each treatment group because the total number was often quite low (particularly for neoplasms). a Percentage of lesion-bearing animals. b Administered by oral gavage 3 times/week. c Because no variation existed in the treated group, and all measures of centrality were less than for the control group, no statistical analysis was performed for renal carcinoma.
None of the other comparisons were signi cantly different from the control.
Nonrenal Neoplasms: None of the 3 carcinogens (2,4-DAT, 2-NP, or furan) produced a hepatic or biliary response comparable to that observed with the same chemical in previously published 2-year bioassays. One hepatocellular carcinoma and 1 epididymal leiomyoma in rats treated with 2-nitropropane were the only nonrenal neoplasms observed in Phase I. In Phase II, there were no nonrenal neoplasms in the furan-treated group. Four nonrenal neoplasms were observed, 2 in control animals and 2 in cyclosporine-treated animals. These were a splenic lymphoma with involvement of other organs in 1 rat in the water control group; a splenic hemangioma in 1 animal in the olive oil control group; a keratoacanthoma in 1 rat in the cyclosporine-treated group; and an epididymal leiomyoma in 1 rat in the cyclosporine-treated group. All of these neoplasms were considered incidental to treatment.
Nonrenal
Carcinogens-Renal Hyperplasia, and Neoplasia: None of the genotoxic nonrenal carcinogens (2,4-DAT, 2-NP, or furan) increased the background incidence or severity of chronic progressive nephropathy (CPN) in Eker rats or produced any apparent separate nephrotoxic effect. The mean number of renal hyperplastic tubules was approximately 1.5 times higher in 2,4-DATtreated animals compared to the controls ( p 0.0347), but the mean numbers of hyperplastic tubules in rats treated with either 2-NP or furan were comparable to the respective control values. The incidence of renal tubular hyperplasia was comparable in animals treated with nonrenal genotoxic carcinogens and their concurrent controls.
The mean numbers of renal adenomas were higher in 2,4-DAT and 2-NP-treated groups (1.2 and 2.2 times, respectively) compared to the concurrent vehicle or untreated control groups. However, the mean numbers of renal adenomas were comparable in furan-treated rats compared to their concurrent vehicle or untreated controls. The incidence of renal adenomas was higher in furan-treated rats compared to their concurrent vehicle or untreated controls, but in 2,4-DAT and 2-NP-treated rats the incidences of adenomas were comparable to their respective control groups.
Mean numbers of renal carcinomas were statistically signi cantly increased in 2,4-DAT-treated rats ( p 0.0413) when compared to their concurrent vehicle or untreated controls, but were not observed at all in 2-NP-treated rats. Mean numbers of renal carcinomas observed in the furan-treated group were comparable to those observed in the control groups. The incidence of carcinomas was slightly higher in 2,4-DAT and furan-treated rats compared to their controls, but the differences were very slight and were not statistically signi cant.
Noncarcinogeni c Nephrotoxins-Nephrotoxicity : Both nephrotoxic compounds produced a characteristic pattern of renal lesions. Al-NTA produced tubular epithelial changes a Percentage of lesion-bearing animals. b Administered by intraperitoneal injection 3 times/week. c p < 0.001 (Al-NTA compared to sterile water). d p 0.036 (Al-NTA compared to sterile water). e p 0.0072 (Al-NTA compared to sterile water).
including cytoplasmic amphophilia and granularity, swelling and vacuolar degeneration, and necrosis and regeneration. Many tubular lumina contained proteinaceous and/or cellular debris, but few casts were observed. Variable degrees of tubular basement membrane thickening and interstitial brosis were present, primarily in the cortex. Hypertrophy of glomerular mesangial cells with cytoplasmic swelling and blue-gray discoloration (interpreted as intracellular aluminum) was also observed.
A combination of nephrocalcinosis and a nonspeci c nephropathy was observed in cyclosporine-treated rats. Nephropathy attributed to cyclosporine administration was characterized primarily by medullary and cortical interstitial brosis with tubular basement membrane thickening, glomerular capsular thickening, and tubular atrophy and/or dilatation. The cyclosporine-induced changes were not clearly distinct from chronic progressive nephropathy (CPN) but tended to more consistently involve the medulla, as well as the cortex, and lacked the tubular cytoplasmic protein droplets and protein casts usually characteristic of CPN.
Noncarcinogenic Nephrotoxins-Renal Hyperplasia, and Neoplasia: Numbers of renal hyperplastic tubules and numbers and incidence of renal adenomas and total tumors were all signi cantly increased, at both the 4-and 6-month time points, in rats treated with either Al-NTA (Tables 7 and  8) or cyclosporine (Tables 9 and 10 ) when compared to their concurrent vehicle controls. The increases in numbers and incidence of total tumors were almost entirely a re ection of the increases in renal adenomas, because extrarenal neoplasms occurred only in 2 cyclosporine-treated rats and the numbers of renal carcinomas were comparable between treated and control rats.
With both Al-NTA and cyclosporine, slight or moderate increases in incidence and numbers of all neoplasms (primarily re ecting renal neoplasms) were observed with extension of the treatment duration from 4 to 6 months. However, a comparable or even greater increase was observed in untreated rats, suggesting that these increases were related to age and not to treatment. This observation is consistent with the nding that duration of exposure had a statistically signi cant effect ( p 0.0019) on renal adenoma and total tumor counts and incidence, but the treatment by duration interactions were not statistically signi cant.
Other Nonneoplastic Lesions: All of the compounds used in these studies produced characteristic histopathologi c effects in expected target organs and/or other effects related to expected pharmacologic activity (data not shown).
DISCUSSION
These studies suggest that the Eker rat model has limited ability to predict the outcome of the standard 2-year carcinogenesis bioassay, either by reduced latency to the same endpoints or by a response in a genetically susceptible tissue (i.e., the kidney). Although there were occasional statistically signi cant differences between treated and control animals for some renal proliferative lesions, including an increase in renal carcinomas in 2,4-DAT treated Eker rats, there were no distinct patterns or trends of response to suggest that this was indicative of an early "reporter" response to carcinogen treatment. There were also no apparent qualitative or quantitative differences in the hepatic response of Eker rats, compared to wild-type Long Evans rats, treated with either 2,4-diaminotoluene (2,4-DAT) or 2-nitropropane (2-NP) for 4 months. Incidence and severity of compound-induced hepatic changes were comparable between genotypes (data not shown). No biliary neoplasms were induced in Eker rats following 4 or 6 months treatment with furan, and the hepatic changes induced by furan treatment were comparable to those previously reported for similar treatment durations (14) . These results are consistent with previous observations that the Eker rat does not display an increased sensitivity to experimental induction of tumor types other than renal epithelial neoplasms, suggesting that even germline conferred susceptibility to chemical carcinogens may be tissue or celltype speci c (18) .
Administration of nephrotoxic, noncarcinogenic compounds (Al-NTA and cyclosporine) produced a statistically signi cant increase in the number of preneoplastic and neoplastic renal lesions in the Eker rat compared to concurrent vehicle or untreated controls after 4 months of treatment. Within each treatment group, the mean numbers of neoplastic renal lesions generally increased from 4 months to 6 months. This effect seemed independent of treatment and was attributed to aging rather than compound administration. The results of nephrotoxin treatment are consistent with recent observations regarding the effects of treating Eker rats with compounds, such as estrogen and hydroquinone, that are converted to nephrotoxic reactive metabolites by c -glutamyl transpeptidase within the renal tubular brush border. Estrogen, which is metabolized to reactive catechol estrogens, exacerbates the incidence and severity of spontaneous nephropathy in Eker rats and also increases the numbers of renal neoplastic and preneoplastic lesions. Hydroquinone is metabolized to 2,3,5-tris-(glutathion-S-yl)HQ, a potent nephrotoxin and redox active compound, and also increases numbers and incidence of renal preneoplastic and neoplastic lesions in Eker rats (13, 19) .
There was no statistically signi cant effect of treatment at either 4 or 6 months on renal carcinoma numbers or incidence, but the actual numbers of carcinomas were slightly higher in Al-NTA and cyclosporine treated animals. This paralleled the increase in adenomas and hyperplastic tubules and is consistent with the effects of other nephrotoxic agents that cause increased numbers of preneoplastic and neoplastic renal lesions, but no shift in the ratio of benign to malignant neoplasms (13, 19) . Nephrotoxic insults associated with tubular regeneration and hyperplasia could potentially enhance xation of spontaneous mutations in the Eker, effectively acting as "initiators" in this model (4, 13) .
These ndings suggest that spontaneous renal neoplasia in the Eker rat can be ampli ed by the administration of exogenous nephrotoxins, even if these compounds are themselves noncarcinogens. There is no evidence that Eker rats respond sooner to nonnephrotoxi c carcinogens than do wild-type rats, although some carcinogens may increase the incidence or multiplicity of renal neoplasms in this model. A 4-or 6-month study in Eker rats does not appear to be a reliable predictor of the results of a 2-year rodent carcinogenesis bioassay.
